An act relating to fiscal year 2027 Opioid Abatement Special Fund and Substance Misuse Prevention Special Fund appropriations
H.660 is a fiscal year 2027 appropriations bill that directs money from Vermont’s Opioid Abatement Special Fund and Substance Misuse Prevention Special Fund to a wide range of opioid response, recovery, harm-reduction, and youth prevention programs. The bill funds Department of Health outreach and case-management staff, recovery residences, syringe services, peer recovery coaches in correctional settings, homelessness-related supports, new recovery and treatment beds, EMS buprenorphine training, transitional housing subsidies, public safety enhancement coordination, and youth-focused prevention and recovery services in several communities.
The bill also revises the statutory framework governing the Opioid Settlement Advisory Committee and the two special funds. It requires broader consultation with people with lived experience and other stakeholders, adds sustainability-plan expectations for ongoing funding proposals, directs quarterly reporting on unspent balances, and changes how future spending proposals are handled. It includes a plan for reviewing prior appropriations and, for fiscal year 2028, suspends new funding proposals from the Opioid Abatement Special Fund unless a program is already identified in statute as annual funding, while the committee reviews outcomes and long-term sustainability instead.
The bill would amend 18 V.S.A. §§ 4772, 4774, and 4812 and make multiple one-time and ongoing appropriations from the Opioid Abatement Special Fund and the Substance Misuse Prevention Special Fund. It would also redirect or restore certain prior appropriations, require the Department of Health to report quarterly on expenditures and unspent balances, and require a syringe recovery implementation plan. In practical terms, it expands and formalizes state funding for opioid treatment, recovery, harm reduction, and prevention programs while tightening legislative oversight of settlement-fund spending and setting up a review of whether some programs should eventually move to other funding sources.
The overall sentiment reflected in the bill is supportive of continued and expanded investment in opioid abatement and substance misuse prevention, with a strong emphasis on treatment, recovery supports, and community-based services. The bill’s structure suggests broad legislative interest in preserving funding for programs already viewed as important, while also increasing accountability and planning for sustainability. The recorded vote history shows at least one failed amendment motion on the Senate side, indicating some disagreement over the bill’s details even though the measure is presented as having passed both chambers in the text provided.
The main points of contention appear to be how opioid settlement dollars should be allocated, whether certain programs should be funded annually from the special fund, and how quickly the state should shift some recurring costs to other funding sources such as the General Fund. The bill specifically highlights debate-prone areas such as syringe services, overdose prevention centers, recovery residences versus treatment beds, and funding for correctional and public-safety-related interventions. The suspension of new fiscal year 2028 proposals and the requirement for sustainability plans also suggest concern about overreliance on settlement funds and disagreement over which programs merit continued support.